Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 11, 2020, reporting the issuance and sale of $2 billion in aggregate principal amount of senior unsecured notes. This issuance includes $1.25 billion of 1.750% Senior Notes due 2030 and $750 million of 2.800% Senior Notes due 2050. The net proceeds of approximately $1,977 million were primarily used to fully repay the $1.5 billion Sanofi Repurchase Bridge Facility, along with associated interest and fees. This debt issuance represents a significant financial maneuver for Regeneron, enabling it to refinance existing debt and potentially free up capital. The new notes are senior unsecured obligations, ranking equally with other senior unsecured debt but subordinate to secured debt and structurally subordinate to subsidiary obligations. The terms include redemption options and a change-of-control provision requiring a repurchase offer under specific circumstances.
Key Highlights
- 1Regeneron issued $1.25 billion of 1.750% Senior Notes due 2030 and $750 million of 2.800% Senior Notes due 2050, totaling $2 billion in aggregate principal amount.
- 2Net proceeds from the note offering were approximately $1,977 million.
- 3The proceeds were used to fully repay the $1.5 billion Sanofi Repurchase Bridge Facility, plus accrued interest and fees.
- 4The new notes are senior unsecured obligations of the company.
- 5The 2030 Notes mature on September 15, 2030, and the 2050 Notes mature on September 15, 2050.
- 6Interest on both series of notes is payable semi-annually.
- 7The notes contain redemption provisions and a change-of-control repurchase option.